Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
GANX Stock Chart & Stats
$3.15
-$0.01(-0.44%)
At close: 4:00 PM EST
$3.15
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)1.72M
Market Cap
$121.16M
Enterprise Value$0.00
Total Cash (Recent Filing)$8.81M
Total Debt (Recent Filing)$180.94K
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding38,462,086
10 Day Avg. Volume2,904,569
30 Day Avg. Volume1,722,662
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.73
Price to Sales (P/S)0.00
P/FCF Ratio-2.62
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$7.60Price Target Upside141.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentGain Therapeutics is planning to submit an Investigational New Drug application to the FDA, facilitating expansion into Phase 2 clinical development of GT-02287.
Mechanism Of ActionPreclinical models of GT-02287 show enhanced GCase activity, reduced neuroinflammation, neuron protection, and improved motor performance.
Safety And EfficacyGT-02287 was generally well tolerated with no treatment emergent serious adverse events and more than half of the participants currently opting to continue dosing in Part 2.
Bears Say
Clinical Data VariabilityThe clinical endpoints shown for individual patients were, as expected, very noisy.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics’s market cap?
Gain Therapeutics’s market cap is $121.16M.
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 79 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.161 by $0.011.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 38,462,086 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.161. Following the earnings report the stock price went up 10.075%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.60 (141.27% Upside)
$7.60 (141.27% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.87%
12-Months-Change
Fundamentals
Return on Equity
-261.72%
Trailing 12-Months
Asset Growth
-23.63%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.60
▲(141.27% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.33%
Insiders
1.66% Mutual Funds
2.15% Other Institutional Investors
91.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---